CD58 and B-cell acute lymphoblastic leukemia: Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B‐cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).